- CELG Stock Page
Celgene Corp. (NASDAQ-GS:CELG)
Last Update: 16 minutes ago
| Change: | -2.80 (-3.88%) |
| Last Trade: | 69.45 |
| Prev Close: | 72.25 |
| Share Volume: | 4,686,314 |
| Market Cap: | 30.27B |
| EPS (Earnings per share): | -3.58 |
| P/E (Price/earning ratio): | N/A |
| P/B (Price/book ratio): | 9.99 |
| Stock Price History | |
|---|---|
| Beta: | 0.44 |
| 52 week change: | 22.40% |
| 52 week high: | 75.44 |
| 52 week low: | 41.26 |
| 50 day moving avarage: | 64.98 |
| 200 day moving avarage: | 60.17 |
| Dividends | |
| Ex dividend date: | N/A |
| Dividend yield: | N/A |
| Dividend rate: | N/A |
| Share Statistics | |
| Avarage 10 day volume: | 4,646,514 |
| Shares outstanding: | 435,866,274 |
| Short interest date: | Jun 25, 2008 |
| Short shares: | 12,998,793 |
| Short ratio: | 3.90 |
| Short % of float: | 3.00% |
| Today | 5d | 1m | 3m | 6m | 1y | 5y |
Latest Headlines for CELG
-
Jul 18 at 7:31 ET
Celgene Corporation to Announce Second Quarter 2008 Results
Company Profile
Sector: Healthcare
Industry: Drugs
Biophamaceutical co. focused on cancer therapies
A biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.
CELG Headlines
-
Jul 18 at 7:31 ET
Celgene Corporation to Announce Second Quarter 2008 Results -
Jul 01 at 10:50 ET
Seven Summits Research Releases Comments on GOOG, ABX, CELG, RF, and BKC -
Jun 20 at 9:31 ET
Seven Summits Research Releases Alerts on GS, WB, OXY, PCX, and CELG -
Jun 19 at 7:42 ET
Celgene Corporation to Present at Jefferies 2nd Annual Healthcare Conference -
Jun 17 at 7:31 ET
Clinical Data For REVLIMID(R) And VIDAZA(R) In Important Blood Cancers Presented at The 13th European Hematology Association Congress -
Jun 17 at 7:30 ET
Celgene Corporation to Present at William Blair & Company's 28th Annual Growth Stock Conference -
Jun 16 at 9:41 ET
REVLIMID(R) Data for Newly Diagnosed Multiple Myeloma Reported at a Satellite Symposium During the 13th European Hematology Association Congress -
Jun 14 at 12:15 ET
Health Economic Analysis Reports That Revlimid is a Cost Effective Treatment for Multiple Myeloma -
Jun 14 at 5:43 ET
Preliminary Results from International Study Report That REVLIMID(R) Provides Responses for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma -
Jun 14 at 5:11 ET
New Analysis of Phase III Studies Shows That REVLIMID(R) Plus Dexamethasone Yielded an Estimated Mean Survival of 5.6 Life Years for Patients with Multiple Myeloma
